- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03080116
Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy (ARNEO)
Neoadjuvant Degarelix +/- Apalutamide (ARN-509) Followed by Radical Prostatectomy for Intermediate and High-risk Prostate Cancer: a Randomized, Placebo-controlled Trial
RATIONALE: Neoadjuvant hormonal therapy using luteinizing hormone releasing hormone (LHRH) agonists and/or anti-androgens has already demonstrated to downstage primary prostate cancer in patients treated by radical prostatectomy without a survival benefit. There is no evidence yet of a survival impact of LHRH antagonist (LHRHa) +/- new-generation anti-androgens in this setting. Thus novel studies are needed to assess this treatment combination.
PURPOSE: To assess the difference in treatment antitumor effect between arms by measuring pathological tumor volume with minimal residual disease (MRD) following radical prostatectomy + pelvic lymph-node dissection (RP + PLND) for intermediate or high-risk prostate cancer patients.
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE: To assess the difference in antitumor effect between the treatment arms by measuring MRD following radical prostatectomy.
SECONDARY OBJECTIVES: To measure differences between study arms in
- Proportions of post neoadjuvant prostate specific antigen (PSA) ≤ 0.3 ng/ml as a predictor of prostate cancer mortality
- T down-staging, complete pathological response, PSA kinetics, Testosterone kinetics, operation time, blood loss, grade of surgical difficulty
- New generation hybrid imaging 68Ga PSMA (Prostate-Specific Membrane Antigen) PET/MR (Positron emission tomography/Magnetic Resonance) derived parameters
- Early biochemical recurrence as prognostic factor of prostate cancer mortality
- Transcriptome and genome
- Tissue microarrays (TMA) protein expression (DNA repair, resistance etc.) by immunohistochemistry
- Perioperative safety and tolerability
- Quality of life, erection recovery, continence through validated preoperative and postoperative questionnaires pre and postop (IEEF5, ICIQ, EORTC QLQ-C30)
OUTLINE: interventional, single center, phase II, randomized, double blind, placebo controlled trial.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Steven Joniau, MD PhD
- Phone Number: +32 16 34 66 87
- Email: steven.joniau@uzleuven.be
Study Contact Backup
- Name: Lorenzo Tosco, MD
- Phone Number: +32 16 34 66 87
- Email: lorenzo.tosco@uzleuven.be
Study Locations
-
-
Vlaams-brabant
-
Leuven, Vlaams-brabant, Belgium, 3000
- Recruiting
- University Hospitals Leuven
-
Contact:
- Gaëtan Devos, MD
- Email: gaetan.devos@uzleuven.be
-
Contact:
- Steven Joniau, Prof. MD
- Email: steven.joniau@uzleuven.be
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations
- Male aged 18 years or older (within 80 years)
- Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
- Diagnosis of intermediate (at least 2 of the following factors: cT2b, biopsy GS 7, PSA 10-20ng/ml) or high-risk prostatic adenocarcinoma (clinical stage≥T2c and/or biopsy GS≥8 and/or PSA>20ng/ml), cN0-cN1, cM0.
- Patient amenable for open or robotic radical prostatectomy + pelvic lymph node dissection
- ECOG performance status: 0-1
Adequate organ function as defined by the following criteria:
- White blood cells (WBC) ≥ 4.0 x109/L
- Platelet count ≥ 100 x109/L
- Hemoglobin ≥9 g/dl
- Creatinine ≤ 2 x ULN
- Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) ≤ 2.5 x upper limit of normality (ULN)
- Total serum bilirubin ≤1.5 x ULN.
Exclusion Criteria:
- Previous surgical/endoscopic treatments for prostatic disease
- Herbal and non-herbal products that in the opinion of the investigator may decrease PSA levels
- cM1 disease
- Any contraindication for PET or MR investigations
- History of seizure or condition that may pre-dispose to seizure (e.g., prior stroke within 1 year prior to randomization, brain arteriovenous malformation, Schwannoma, meningioma, or other benign CNS or meningeal disease which may require treatment with surgery or radiation therapy)
- Medications known to lower the seizure threshold
History of:
- Any prior malignancy (other than adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer currently in complete remission) within 5 years prior to randomization
- Severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to randomization
- Uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic BP ≥100 mmHg). Patients with a history of uncontrolled hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment.
- Gastrointestinal disorder affecting absorption
- Any other condition that, in the opinion of the Investigator, would impair the patient's ability to comply with study procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ARN-509 + degarelix
Treatment period of 12 weeks before RP + PLND.
|
240mg/day (4x60mg tablets, Oral administration: OS)
Other Names:
1st injection: 120mg Subcutaneous administration (SC) x2, 2nd-3rd SC injection 80mg monthly
|
ACTIVE_COMPARATOR: placebo + degarelix
Treatment period of 12 weeks before RP + PLND.
|
1st injection: 120mg Subcutaneous administration (SC) x2, 2nd-3rd SC injection 80mg monthly
4 tablets, per OS
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Minimal Residual Disease (MRD)
Time Frame: After 12 weeks of neoadjuvant therapy + RP + PLND
|
Proportions of MRD between arms.
MRD: tumor volume ≤ 0.25 cm3
|
After 12 weeks of neoadjuvant therapy + RP + PLND
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in proportions of pathological downstage
Time Frame: After 12 weeks of neoadjuvant therapy + RP + PLND
|
Any decrease in T stage from clinical to pathological stage
|
After 12 weeks of neoadjuvant therapy + RP + PLND
|
Complete pathological response rates
Time Frame: After 12 weeks of neoadjuvant therapy + RP + PLND
|
Difference in proportions of complete pathological response (no evidence of tumour in the postoperative specimen) between arms.
|
After 12 weeks of neoadjuvant therapy + RP + PLND
|
Difference in proportions of patients with pN1 disease.
Time Frame: After 12 weeks of neoadjuvant therapy + RP + PLND
|
Difference in proportions of lymph node invasion between arms
|
After 12 weeks of neoadjuvant therapy + RP + PLND
|
Proteins expression in prostatic tumour TMA's (tissue microarrays)
Time Frame: After 12 weeks of neoadjuvant therapy + RP + PLND
|
Intensity of immunoreactivity and percentage of immunoreactive cells for, selected markers between arms.
The TMA's will be produced from the formalin-fixed paraffin-embedded (FFPE) specimen of the RP.
|
After 12 weeks of neoadjuvant therapy + RP + PLND
|
Transcriptome analysis by microarray expression platform
Time Frame: At baseline and after 12 weeks of neoadjuvant therapy + RP + PLND
|
To assess differences in the transcriptome in tumour tissue on formalin-fixed paraffin-embedded (FFPE) specimens: clinical-grade high-density oligonucleotide microarray expression platform and cloud-based informatics pipeline to interrogate 1.4M probe sets representing all known ~46K genes and non-coding RNAs.
|
At baseline and after 12 weeks of neoadjuvant therapy + RP + PLND
|
Pathway profiling and Gene Set Enrichment Analyses
Time Frame: At baseline and after 12 weeks of neoadjuvant therapy + RP + PLND
|
To assess differences in the transcriptome in tumour tissue on formalin-fixed paraffin-embedded (FFPE) specimens.
Pathway profiling and Gene Set Enrichment Analyses will also be used to generate pathway scores for the 'androgen receptor signaling pathway'; determination of pathway scores for the DNA damage checkpoints and the different DNA repair pathways.
|
At baseline and after 12 weeks of neoadjuvant therapy + RP + PLND
|
Genomic subtyping by exome-sequencing
Time Frame: At baseline and after 12 weeks of neoadjuvant therapy + RP + PLND
|
Genomic subtyping (e.g., ERG, SPINK1, SPOP, FOXA1, PTEN, circulating nucleic acids (CNA) data...) will be performed based on exome-sequencing data.
The exome and CNA data will be linked with the transcriptome data on androgen regulation and DNA repair pathways.
|
At baseline and after 12 weeks of neoadjuvant therapy + RP + PLND
|
PSA kinetics
Time Frame: Up to 40 months
|
Changes of PSA during time and comparison of PSA values and changes between arms.
|
Up to 40 months
|
Testosterone kinetics
Time Frame: Up to 40 months
|
Comparison of total and free serum testosterone and testosterone change between arms
|
Up to 40 months
|
PSA nadir </=0.3ng/ml after neoadjuvant treatment
Time Frame: After 12 weeks of neoadjuvant therapy before RP + PLND
|
Differences in proportions of PSA nadir </=0.3ng/ml after neoadjuvant treatment. PSA nadir after neoadjuvant therapy and before external beam radiotherapy (EBRT) is an important biomarker of hormonal response and an independent prognostic factor of prostate cancer survival. |
After 12 weeks of neoadjuvant therapy before RP + PLND
|
Peri-operative features
Time Frame: up to (about) 5 hours
|
Differences in peri-operative features (operative time, blood loss, grade of surgical difficulty...) will be collected to evaluate the possible effect of treatment on surgical intervention.
|
up to (about) 5 hours
|
Differences in proportions of surgical complications between arms
Time Frame: Up to 6 weeks post RP + PLND
|
Clavien-Dindo classification will be implemented to assess differences in surgical complications between the two arms.
|
Up to 6 weeks post RP + PLND
|
Continence
Time Frame: Up to 40 months
|
Assessment of continence rates through validated preoperative and postoperative questionnaire (ICIQ)
|
Up to 40 months
|
Quality of life
Time Frame: Up to 40 months
|
Assessment of Quality of life through validated preoperative and postoperative questionnaire (EORTC QLQ-C30)
|
Up to 40 months
|
Erection state
Time Frame: Up to 40 months
|
Assessment of erection state through validated preoperative and postoperative questionnaire (IEEF5)
|
Up to 40 months
|
Survival
Time Frame: Up to 36 months
|
Three years biochemical recurrence free survival
|
Up to 36 months
|
Standardized Uptake Value (SUV) on pelvic [68]Ga PSMA PET/MR per arm
Time Frame: At baseline and after 12 weeks of neoadjuvant therapy + RP + PLND
|
Standardized Uptake Value (SUV) change (delta) per arm comparing SUV values before and after treatment
|
At baseline and after 12 weeks of neoadjuvant therapy + RP + PLND
|
Standardized Uptake Value (SUV) on pelvic [68]Ga PSMA PET/MR between arms
Time Frame: After 12 weeks of neoadjuvant therapy + RP + PLND
|
SUV delta between the two arms.
|
After 12 weeks of neoadjuvant therapy + RP + PLND
|
Standardized Uptake Value (SUV) on pelvic [68]Ga PSMA PET/MR and tumour volume
Time Frame: After 12 weeks of neoadjuvant therapy + RP + PLND
|
Correlation between SUV values and the tumour volume (TV) in the RP correspondent volume of interest (VOI) at definitive pathology
|
After 12 weeks of neoadjuvant therapy + RP + PLND
|
Standardized Uptake Value (SUV) on prostate [68]Ga PSMA PET/MR and Immunohistochemistry
Time Frame: After 12 weeks of neoadjuvant therapy + RP + PLND
|
Correlation between SUV values and PSMA expression at Immunohistochemistry
|
After 12 weeks of neoadjuvant therapy + RP + PLND
|
Magnetic resonance (MR) and tumor volume (TV) per arm
Time Frame: At baseline and after12 weeks of neoadjuvant therapy + RP + PLND
|
Change of magnetic resonance (MR) tumor volume (TV): Tumor volume (TV) change (delta) per arm comparing TV values before and after treatment
|
At baseline and after12 weeks of neoadjuvant therapy + RP + PLND
|
Magnetic resonance (MR) and tumor volume (TV) between arms
Time Frame: At baseline and after12 weeks of neoadjuvant therapy + RP + PLND
|
Change of magnetic resonance (MR) tumor volume (TV):TV deltas between the two arms.
|
At baseline and after12 weeks of neoadjuvant therapy + RP + PLND
|
PI-RADS between arms at MR
Time Frame: After 12 weeks of neoadjuvant therapy + RP + PLND
|
Proportion of PI-RADS between arms
|
After 12 weeks of neoadjuvant therapy + RP + PLND
|
PI-RADS score and Gleason score
Time Frame: After 12 weeks of neoadjuvant therapy + RP + PLND
|
Correlation between PI-RADS score and pathology Gleason score
|
After 12 weeks of neoadjuvant therapy + RP + PLND
|
Down-staging at imaging
Time Frame: At baseline and after 12 weeks of neoadjuvant therapy + RP + PLND
|
Proportion of down-staging
|
At baseline and after 12 weeks of neoadjuvant therapy + RP + PLND
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: From patient inclusion until RP + PLND
|
Frequencies of adverse events (AE), severe adverse events (SAE) and Suspected Unexpected Serious Adverse Reaction (SUSAR)
|
From patient inclusion until RP + PLND
|
Collaborators and Investigators
Investigators
- Principal Investigator: Steven Joniau, UZ Leuven
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- S58827
- 2016-002854-19 (EUDRACT_NUMBER)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on ARN-509
-
Aragon Pharmaceuticals, Inc.Active, not recruiting
-
Aragon Pharmaceuticals, Inc.Completed
-
Janssen Research & Development, LLCCompleted
-
Institut Paoli-CalmettesJanssen-Cilag Ltd.UnknownLow Risk Prostate CancerFrance
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingProstate Adenocarcinoma | Stage IIB Prostate Cancer AJCC v8United States
-
Aragon Pharmaceuticals, Inc.Completed
-
University of WashingtonNational Cancer Institute (NCI); Janssen Scientific Affairs, LLCTerminatedProstate AdenocarcinomaUnited States
-
National Cancer Institute (NCI)RecruitingProstate Adenocarcinoma | Localized Prostate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8United States
-
National Cancer Institute (NCI)Not yet recruitingNon-Muscle Invasive Bladder Urothelial Carcinoma | Recurrent Non-Muscle Invasive Bladder Urothelial CarcinomaUnited States
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingPSA Progression | Stage III Prostate Adenocarcinoma | Stage IV Prostate AdenocarcinomaUnited States, Canada